Literature DB >> 22907859

Refractory calcinosis in a patient with dermatomyositis: response to intravenous immune globulin.

Lokesh Shahani1.   

Abstract

Dermatomyositis is an inflammatory myopathy and commonly presents with progressive, symmetric proximal muscle weakness and cutaneous findings. Calcinosis is a severe manifestation that can be debilitating. The cutaneous manifestations of dermatomyositis may also develop in the absence of detectable muscle disease, and can persist after the successful treatment of myositis. The author reports a 30-year-old woman with biopsy-proven dermatomyositis who had failed previous trials of azathioprine and methotrexate. Her muscle weakness was controlled with mycophenolate mofetil and prednisone; however, she had recurrent attacks of painful calcinosis. The patient responded to intravenous immune globulin (IVIG) along with intravenous methylprednisone, followed by IVIG for 2 consecutive days each month. This regimen has been effective in preventing recurrence of her calcinosis. This case illustrates the cutaneous manifestation of dermatomyositis, which is often more refractory to treat as compared to the muscle involvement and require additional approaches such as IVIG.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22907859      PMCID: PMC4544600          DOI: 10.1136/bcr-2012-006629

Source DB:  PubMed          Journal:  BMJ Case Rep        ISSN: 1757-790X


  3 in total

1.  Calcinosis cutis associated with amyopathic dermatomyositis: response to intravenous immunoglobulin.

Authors:  Yeray Peñate; Noemi Guillermo; Priti Melwani; Rosa Martel; Buenaventura Hernández-Machín; Leopoldo Borrego
Journal:  J Am Acad Dermatol       Date:  2009-06       Impact factor: 11.527

Review 2.  The management of dermatomyositis: current treatment options.

Authors:  Richard D Sontheimer
Journal:  Expert Opin Pharmacother       Date:  2004-05       Impact factor: 3.889

3.  A controlled trial of high-dose intravenous immune globulin infusions as treatment for dermatomyositis.

Authors:  M C Dalakas; I Illa; J M Dambrosia; S A Soueidan; D P Stein; C Otero; S T Dinsmore; S McCrosky
Journal:  N Engl J Med       Date:  1993-12-30       Impact factor: 91.245

  3 in total
  5 in total

Review 1.  The presentation, assessment, pathogenesis, and treatment of calcinosis in juvenile dermatomyositis.

Authors:  Mark F Hoeltzel; Edward J Oberle; Angela Byun Robinson; Arunima Agarwal; Lisa G Rider
Journal:  Curr Rheumatol Rep       Date:  2014-12       Impact factor: 4.592

Review 2.  Intravenous immunoglobulins for treatment of connective tissue diseases in dermatology.

Authors:  Lyubomir A Dourmishev; Dimitrina V Guleva; Ljubka G Miteva
Journal:  Wien Med Wochenschr       Date:  2017-09-01

Review 3.  Subcutaneous calcinosis: Is it different between systemic sclerosis and dermatomyositis?

Authors:  Antonia Valenzuela; Lorinda Chung
Journal:  J Scleroderma Relat Disord       Date:  2021-10-28

Review 4.  The Value of Intravenous Immunoglobulin Therapy in Idiopathic Inflammatory Myositis in the Current Transformed Era of Biologics.

Authors:  Anjali Patwardhan
Journal:  Cureus       Date:  2020-02-19

Review 5.  Biologics in dermatology: an integrated review.

Authors:  Virendra N Sehgal; Deepika Pandhi; Ananta Khurana
Journal:  Indian J Dermatol       Date:  2014-09       Impact factor: 1.494

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.